Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review
T Surarak, S Chumnumwat… - Clinical and …, 2024 - Wiley Online Library
Abstract N‐acetyltransferase 2 (NAT2) genetic polymorphisms might alter isoniazid
metabolism leading to toxicity. We reviewed the impact of NAT2 genotype status on the …
metabolism leading to toxicity. We reviewed the impact of NAT2 genotype status on the …
Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection
W Phaisal, O Albitar, P Chariyavilaskul… - Journal of …, 2024 - academic.oup.com
Objectives Twelve weekly doses of rifapentine and isoniazid (3HP regimen) are
recommended for TB preventive therapy in children with TB infection. However, they present …
recommended for TB preventive therapy in children with TB infection. However, they present …
Characterization, comparative, and functional analysis of arylacetamide deacetylase from Gnathostomata organisms
T Diaz-Vidal, CB Romero-Olivas… - Journal of Genetic …, 2022 - Elsevier
Background Arylacetamide deacetylase (AADAC) is a lipolytic enzyme involved in
xenobiotic metabolism. The characterization in terms of activity and substrate preference has …
xenobiotic metabolism. The characterization in terms of activity and substrate preference has …
[PDF][PDF] Clinical Pharmacology of Antituberculosis Drugs in Infants and Children
GM Pacifici - J Case Rep Med Hist, 2022 - acquirepublications.org
The antituberculosis drugs used in paediatric patients are: rifampicin, isoniazid, and
pyrazinamide. The treatment of infections with rifampicin, isoniazid, and pyrazinamide has …
pyrazinamide. The treatment of infections with rifampicin, isoniazid, and pyrazinamide has …
[引用][C] Side effects of drugs used in the treatment of tuberculosis and leprosy
IJ Onakpoya - 2023 - Elsevier